SJY26 is a dual-target inhibitor of PI3K/HDAC, exhibiting IC50 values of 0.59 nM for PI3Kα and PI3Kδ, 2.02 nM for PI3Kγ, 12.69 nM for PI3Kβ, and 114 nM for HDAC1. It has potent antiproliferative activity across a broad spectrum, particularly affecting Jurkat and PC9R cells. SJY26 inhibits the migration of PC9R cells, induces cell cycle arrest, and triggers apoptosis. It also reduces AKT phosphorylation and decreases acetylation of histone H3 (Ac-H3). SJY26 is applicable for research in non-small cell lung cancer and leukemia.

PI3Kα:0.59 nM

SJY26 exhibits potent inhibitory activity against Jurkat, PC9R, MCF-7, and K562 cells, with respective IC50 values of 0.38 μM, 0.59 μM, 1.98 μM, and 4.30 μM. In a concentration-dependent manner, SJY26 (1.25-2.5 μM, 0-48 h) effectively inhibits the migration ability of PC9R cells. Furthermore, SJY26 (2.5 μM, 24 h) causes PC9R cells to arrest in the G2/M phase, preventing mitosis and halting proliferation. SJY26 (2.5-5 μM, 48 h) also induces apoptosis in PC9R cells in a concentration-dependent fashion. Additionally, SJY26 (2.5-5 μM, 24 h) downregulates the PI3K-AKT signaling pathway while upregulating histone acetylation levels in PC9R cells.